Efficacy in Subgroups Related to Disease Characteristics in Patients with Alopecia Areata from BRAVE-AA1 and BRAVE-AA2

    Tiffany Mayo, Susan Taylor, Taisuke Ito, Sergio Vañó Galván, Susan Ball, Na Lü, Chiara Chiasserinio, Yunfei Chen, Brittany G. Craiglow
    Image of study
    TLDR Baricitinib significantly improves hair regrowth in severe alopecia areata.
    The study titled "44096 Efficacy in Subgroups related to Disease Characteristics in Patients with Alopecia Areata from BRAVE-AA1 and BRAVE-AA2" evaluated the efficacy of baricitinib, an oral JAK1/JAK2 inhibitor, in treating adults with severe alopecia areata (AA). The results from the BRAVE-AA1 and BRAVE-AA2 trials demonstrated that baricitinib significantly improved hair regrowth in patients with AA, regardless of disease characteristics. The trials included a substantial number of participants, providing robust evidence for the effectiveness of baricitinib in this patient population. These findings support the use of baricitinib as a treatment option for severe AA in the US, Europe, and Japan.
    Discuss this study in the Community →

    Related Community Posts Join

    6 / 10 results

    Related Research

    1 / 1 results